title: MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
abstract: BACKGROUND
  MicroRNAs (miRNAs) are involved in numerous biological and pathological processes including colorectal cancer (CRC). The aim of our study was to evaluate the ability of miRNA expression patterns to predict chemotherapy response in a cohort of 78 patients with metastatic CRC (mCRC).
  
  
  METHODS
  We examined expression levels of 667 miRNAs in the training cohort and evaluated their potential association with relevant clinical endpoints. We identified a miRNA profile that was analysed by RT-qPCR in an independent cohort. For a set of selected miRNAs, bioinformatic target predictions and pathway analysis were also performed.
  
  
  RESULTS
  Eight miRNAs (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) were significant predictors of response to chemotherapy in the training cohort. In addition, overexpression of miR-107, miR-337-5p and miR-99a-3p, and underexpression of miR-889, were also significantly associated with improved progression-free and/or overall survival. MicroRNA-107 and miR-99a-3p were further validated in an independent cohort as predictive markers for chemotherapy response. In addition, an inverse correlation was confirmed in our study population between miR-107 levels and mRNA expression of several potential target genes (CCND1, DICER1, DROSHA and NFKB1).
  
  
  CONCLUSIONS
  MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC.
authors.forename: Sonia
authors.initials: S
authors.lastname: Molina-Pinelo
authors.forename: Amancio
authors.initials: A
authors.lastname: Carnero
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivera
authors.forename: Purificacion
authors.initials: P
authors.lastname: Estevez-Garcia
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Bozada
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Limon
authors.forename: Marta
authors.initials: M
authors.lastname: Benavent
authors.forename: Javier
authors.initials: J
authors.lastname: Gomez
authors.forename: Maria Dolores
authors.initials: MD
authors.lastname: Pastor
authors.forename: Manuel
authors.initials: M
authors.lastname: Chaves
authors.forename: Rocio
authors.initials: R
authors.lastname: Suarez
authors.forename: Luis
authors.initials: L
authors.lastname: Paz-Ares
authors.forename: Fernando
authors.initials: F
authors.lastname: de la Portilla
authors.forename: Andres
authors.initials: A
authors.lastname: Carranza-Carranza
authors.forename: Isabel
authors.initials: I
authors.lastname: Sevilla
authors.forename: Luis
authors.initials: L
authors.lastname: Vicioso
authors.affiliation: Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Manuel Siurot s/n, 41013 Seville, Spain. rgcarbonero@gmail.com.
authors.forename: Rocio
authors.initials: R
authors.lastname: Garcia-Carbonero
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C549045:MIRN107 microRNA, human; C561679:MIRN99 microRNA, human; D035683:MicroRNAs